JP5795165B2 - 慢性虚血における亜硝酸塩の使用 - Google Patents

慢性虚血における亜硝酸塩の使用 Download PDF

Info

Publication number
JP5795165B2
JP5795165B2 JP2010534267A JP2010534267A JP5795165B2 JP 5795165 B2 JP5795165 B2 JP 5795165B2 JP 2010534267 A JP2010534267 A JP 2010534267A JP 2010534267 A JP2010534267 A JP 2010534267A JP 5795165 B2 JP5795165 B2 JP 5795165B2
Authority
JP
Japan
Prior art keywords
tissue
nitrite
ischemic
pharmaceutical composition
sodium nitrite
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2010534267A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011503212A5 (enExample
JP2011503212A (ja
Inventor
クリストファー ケヴィル
クリストファー ケヴィル
ディヴィッド レファー
ディヴィッド レファー
ラケシュ パテル
ラケシュ パテル
Original Assignee
ルイジアナ ステイト ユニヴァーシティー
ルイジアナ ステイト ユニヴァーシティー
ザ ユーエイビー リサーチ ファンデーション
ザ ユーエイビー リサーチ ファンデーション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ルイジアナ ステイト ユニヴァーシティー, ルイジアナ ステイト ユニヴァーシティー, ザ ユーエイビー リサーチ ファンデーション, ザ ユーエイビー リサーチ ファンデーション filed Critical ルイジアナ ステイト ユニヴァーシティー
Publication of JP2011503212A publication Critical patent/JP2011503212A/ja
Publication of JP2011503212A5 publication Critical patent/JP2011503212A5/ja
Application granted granted Critical
Publication of JP5795165B2 publication Critical patent/JP5795165B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2010534267A 2007-11-15 2008-11-17 慢性虚血における亜硝酸塩の使用 Expired - Fee Related JP5795165B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US315007P 2007-11-15 2007-11-15
US61/003,150 2007-11-15
PCT/US2008/083830 WO2009065142A2 (en) 2007-11-15 2008-11-17 Use of nitrite salts in chronic ischemia

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014097072A Division JP5908527B2 (ja) 2007-11-15 2014-05-08 慢性虚血における亜硝酸塩の使用

Publications (3)

Publication Number Publication Date
JP2011503212A JP2011503212A (ja) 2011-01-27
JP2011503212A5 JP2011503212A5 (enExample) 2012-02-16
JP5795165B2 true JP5795165B2 (ja) 2015-10-14

Family

ID=40639493

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2010534267A Expired - Fee Related JP5795165B2 (ja) 2007-11-15 2008-11-17 慢性虚血における亜硝酸塩の使用
JP2014097072A Expired - Fee Related JP5908527B2 (ja) 2007-11-15 2014-05-08 慢性虚血における亜硝酸塩の使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2014097072A Expired - Fee Related JP5908527B2 (ja) 2007-11-15 2014-05-08 慢性虚血における亜硝酸塩の使用

Country Status (7)

Country Link
US (2) US9649334B2 (enExample)
EP (1) EP2219657A4 (enExample)
JP (2) JP5795165B2 (enExample)
CN (1) CN101939014B (enExample)
AU (1) AU2008322437B2 (enExample)
IL (1) IL205720A (enExample)
WO (1) WO2009065142A2 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009065142A2 (en) 2007-11-15 2009-05-22 Biomedical Research Foundation Of Northwest Louisiana Use of nitrite salts in chronic ischemia
US8568793B2 (en) 2009-02-11 2013-10-29 Hope Medical Enterprises, Inc. Sodium nitrite-containing pharmaceutical compositions
WO2010147742A2 (en) * 2009-06-18 2010-12-23 Theravasc Inc. Use of nitrite salts in treating tissue damage
CN107260756A (zh) 2009-10-14 2017-10-20 瑟阿瓦斯克有限公司 亚硝酸盐/酯的药物制剂以及其应用
US20130209584A1 (en) * 2009-10-14 2013-08-15 Theravasc Inc. Pharmaceutical formulations of nitrite and uses thereof
CN105358160A (zh) 2013-02-20 2016-02-24 瑟阿瓦斯克公司 亚硝酸盐的药物制剂及其用途
US10517817B2 (en) 2013-05-09 2019-12-31 Syk Technologies, Llc Deep topical systemic nitric oxide therapy apparatus and method
WO2017132275A1 (en) 2016-01-27 2017-08-03 Syk Technologies, Llc Nitric oxide topical application apparatus and methods
KR20200083974A (ko) * 2017-09-05 2020-07-09 엑셀 메드, 엘엘씨 허혈 치료용 헤파린 조성물
WO2020141546A1 (en) 2019-01-02 2020-07-09 Celagenex Research (India) Pvt. Ltd. Synergistic nutritional compositions for pain management
US12459820B2 (en) 2020-06-11 2025-11-04 J. W. Randolph Miller Stabilized and NO2-inhibited nitric oxide generating gels for inhaled nitric oxide therapy

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2914446A (en) 1958-06-26 1959-11-24 Upjohn Co Nitrite stabilized ascorbic acid-cyanocobalamin compositions
US4650484A (en) 1983-02-03 1987-03-17 Alza Corporation Method for treating ischemic conditions
IE64726B1 (en) 1987-11-20 1995-08-23 Elan Corp Plc Pharmaceutical formulations for preventing drug tolerance
US5122384A (en) 1989-05-05 1992-06-16 Kv Pharmaceutical Company Oral once-per-day organic nitrate formulation which does not induce tolerance
US5278192A (en) 1992-07-02 1994-01-11 The Research Foundation Of State University Of New York Method of vasodilator therapy for treating a patient with a condition
US6709681B2 (en) 1995-02-17 2004-03-23 Aberdeen University Acidified nitrite as an antimicrobial agent
US20110196039A9 (en) 1994-10-05 2011-08-11 Kaesemeyer Wayne H Controlled release arginine formulations
US5648101A (en) * 1994-11-14 1997-07-15 Tawashi; Rashad Drug delivery of nitric oxide
US5770645A (en) 1996-08-02 1998-06-23 Duke University Medical Center Polymers for delivering nitric oxide in vivo
US5994444A (en) 1997-10-16 1999-11-30 Medtronic, Inc. Polymeric material that releases nitric oxide
US7371415B1 (en) 1998-04-03 2008-05-13 The Daily Wellness Company Method and composition for improving sexual fitness
US7015876B1 (en) 1998-06-03 2006-03-21 Lear Corporation Heads-up display with improved contrast
US6103275A (en) * 1998-06-10 2000-08-15 Nitric Oxide Solutions Systems and methods for topical treatment with nitric oxide
WO2000003725A1 (en) 1998-07-14 2000-01-27 Paracelsian, Inc. Method for identifying and confirming consistent bio-functionality of natural compositions
JP2002535353A (ja) 1999-01-29 2002-10-22 ロザン ファルマ ゲゼルシャフトミットベシュレンクテルハフツンク 医薬品組成物
GB9905425D0 (en) 1999-03-09 1999-05-05 Queen Mary & Westfield College Pharmaceutical composition
US6314956B1 (en) 1999-09-08 2001-11-13 Duke University Pulmonary delivery of NO group-containing compound in gas form to treat respiratory, cardiac and blood disorders
JP2004505056A (ja) * 2000-07-28 2004-02-19 バイオエナジー　インコーポレイティド 心血管の機能を向上する為の組成物及び方法
GB0119011D0 (en) 2001-08-03 2001-09-26 Univ Aberdeen Treatment of nail infections
EP1492509A1 (en) 2001-12-18 2005-01-05 ALZA Corporation Dosage form providing time-varying patterns of drug delivery
EP1336602A1 (en) 2002-02-13 2003-08-20 Giovanni Scaramuzzino Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases
CA2379211A1 (fr) 2002-03-28 2003-09-28 Institut De Cardiologie De Montreal Utilisation du bleu de methylene pour renverser la reaction hemodynamique exageree induite par la combinaison d'un derive nitre et du sildenafil ou d'une molecule de meme classe (inhibiteur de la phosphodiesterase)
WO2005004884A2 (en) 2003-07-09 2005-01-20 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Use of nitrite salts for the treatment of cardiovascular conditions
JP2007502831A (ja) 2003-08-20 2007-02-15 ニトロメッド インコーポレーティッド ニトロソ化およびニトロシル化心血管化合物、組成物、ならびに使用方法
WO2005023189A2 (en) * 2003-09-03 2005-03-17 Pharmacia Corporation Method of cox-2 selective inhibitor and nitric oxide-donating agent
US7362274B1 (en) * 2004-07-09 2008-04-22 Huan-Cheng Lien Coupled feed-in butterfly shaped left/right hand circularly polarized microstrip antenna
US20060083824A1 (en) 2004-10-20 2006-04-20 Pbm Products Llc Nutritional supplements for glucose intolerant individuals
CA2608651A1 (en) 2005-05-24 2006-11-30 Wellgen, Inc. Compositions and methods for the prevention and treatment of conditions associated with inflammation
CA2641950A1 (en) 2006-02-10 2007-08-23 Mannatech, Inc. All natural multivitamin and multimineral dietary supplement formulations for enhanced absorption and biological utilization
GB0607402D0 (en) 2006-04-12 2006-05-24 Barts & London Nhs Trust Therapeutic composition and use
WO2007149520A2 (en) * 2006-06-21 2007-12-27 Albert Einstein College Of Medicine Of Yeshiva University Compositions for sustained release of nitric oxide, methods of preparing same and uses thereof
CA2678093C (en) 2007-02-26 2017-10-24 Jon Lundberg Performance enhancing composition and use thereof
KR20100014853A (ko) 2007-02-26 2010-02-11 존 런드버그 아질산염 및 질산염의 신규 용도 및 이를 함유하는 조성물
WO2008153762A2 (en) 2007-05-25 2008-12-18 N30 Pharmaceuticals, Llc S-nitrosothiol formulations and storage systems
WO2009065142A2 (en) 2007-11-15 2009-05-22 Biomedical Research Foundation Of Northwest Louisiana Use of nitrite salts in chronic ischemia
US20090196930A1 (en) 2007-12-27 2009-08-06 Aires Pharmaceuticals, Inc. Aerosolized nitrite and nitric oxide -donating compounds and uses thereof
WO2010036236A1 (en) 2008-09-23 2010-04-01 Baker Hughes Incorporated Anchor assembly
US8568793B2 (en) 2009-02-11 2013-10-29 Hope Medical Enterprises, Inc. Sodium nitrite-containing pharmaceutical compositions
WO2010147742A2 (en) 2009-06-18 2010-12-23 Theravasc Inc. Use of nitrite salts in treating tissue damage
CN107260756A (zh) * 2009-10-14 2017-10-20 瑟阿瓦斯克有限公司 亚硝酸盐/酯的药物制剂以及其应用
US20130209584A1 (en) 2009-10-14 2013-08-15 Theravasc Inc. Pharmaceutical formulations of nitrite and uses thereof
WO2012135623A1 (en) 2011-03-31 2012-10-04 Theravasc Inc. Use of nitrites for the treatment of cerebral amyloid angiopathy, age associated dementia, and cognitive decline
US20140112983A1 (en) 2011-04-14 2014-04-24 Theravasc Inc. Nitrite compositions and uses thereof
US9294956B2 (en) 2011-12-29 2016-03-22 Qualcomm Incorporated Application-server-assisted preemptive multicast bearer establishment for real-time low-latency applications
CN105358160A (zh) * 2013-02-20 2016-02-24 瑟阿瓦斯克公司 亚硝酸盐的药物制剂及其用途

Also Published As

Publication number Publication date
JP2014139255A (ja) 2014-07-31
CN101939014A (zh) 2011-01-05
JP5908527B2 (ja) 2016-04-26
US10864229B2 (en) 2020-12-15
US20110311653A1 (en) 2011-12-22
IL205720A0 (en) 2010-11-30
IL205720A (en) 2015-08-31
WO2009065142A2 (en) 2009-05-22
JP2011503212A (ja) 2011-01-27
AU2008322437B2 (en) 2013-11-07
EP2219657A4 (en) 2020-01-08
EP2219657A2 (en) 2010-08-25
US20170312310A1 (en) 2017-11-02
AU2008322437A1 (en) 2009-05-22
US9649334B2 (en) 2017-05-16
CN101939014B (zh) 2016-04-27

Similar Documents

Publication Publication Date Title
JP5908527B2 (ja) 慢性虚血における亜硝酸塩の使用
Koneru et al. Sildenafil‐mediated neovascularization and protection against myocardial ischaemia reperfusion injury in rats: role of VEGF/angiopoietin‐1
US10925890B2 (en) Use of dextran sulfate
US10596188B2 (en) Use of nitrite salts in treating tissue damage
Jia et al. Danshensu enhances cerebral angiogenesis in mice by regulating the PI3K/Akt/Mtor/VEGF signaling Axis
WO2024193321A1 (zh) Glyt1抑制剂在治疗器官纤维化中的应用
Cohen et al. Longitudinal changes in myocardial basic fibroblast growth factor (FGF-2) activity following coronary artery ligation in the dog
CN120459270A (zh) OpiCa1或其纳米脂质体在制备治疗和/或预防心肌纤维化相关疾病药物中的应用
WO2015190989A1 (en) The use of dextran sulfate having an average molecular weight below 10000 da for inducing angiogenisis in a subject
Feng et al. Exogenous SERP1 attenuates restenosis by restoring GLP-1 receptor activity in diabetic rats following vascular injury
HK1152657B (en) Use of nitrite salts in chronic ischemia
HK1152657A (en) Use of nitrite salts in chronic ischemia
CN108685896B (zh) 千层纸素a在制备治疗和/或预防慢性周围血管闭塞性疾病药物中的用途
TWI774059B (zh) Ｃｘｃｌ５中和抗體用於製備預防或治療周邊動脈阻塞疾病的藥物的用途
JP2025502175A (ja) Ｃｏｖｉｄ－１９の治療のための組成物及び方法
JP2025516717A (ja) 血管新生を誘発する薬剤
CN116531387A (zh) 新对叶百部碱在制备治疗肺动脉高压的药物中的应用
Belikoff et al. Hyperbaric Oxygen and Endothelial Responses in Wound Healing and Ischemia–Reperfusion Injury

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20111117

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20111213

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20111215

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130529

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130829

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130905

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131128

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20140108

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140508

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20140508

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20140508

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20140530

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20140718

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20141226

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20150812

R150 Certificate of patent or registration of utility model

Ref document number: 5795165

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees